Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK4 Inhibitor
IRAK4-IN-31 is a selective inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway. This compound exhibits potent inhibitory activity against IRAK4, making it valuable for studying immune signaling and associated pathways. IRAK4-IN-31 is particularly relevant in research related to myelodysplastic syndromes (MDS) and may aid in elucidating therapeutic strategies for hematological malignancies. -
IRAK4 Modulator
IRAK4 modulator-1 is a selective modulator of IRAK4, demonstrating an IC50 of 4.647 μM. This compound is instrumental in the exploration of IRAK-mediated signaling pathways, making it a valuable tool for investigating diseases associated with dysregulated inflammation and immune responses. Researchers can utilize IRAK4 modulator-1 to further understand the role of IRAK4 in various pathological conditions. -
IRAK3 PROTAC Degrader
PROTAC IRAK3 degrader-2 is a potent IRAK3 PROTAC degrader with a DC50 of less than or equal to 50 nM. This compound promotes the ubiquitination and subsequent degradation of the IRAK3 protein, making it a valuable tool for studying immune-related diseases. Its unique design incorporates ligands for E3 ligase and a linker configuration, facilitating targeted degradation and aiding research into therapeutic strategies for modulating immune responses. -
IRAK4 Inhibitor
DW18134 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 11.2 nM. It effectively inhibits the phosphorylation of IRAK4 and IKK, leading to downregulated secretion of pro-inflammatory cytokines TNF-α and IL-6. In preclinical studies, DW18134 demonstrates efficacy in mitigating lipopolysaccharide-induced peritonitis and dextran sulfate sodium-induced colitis in mouse models, while also preserving intestinal barrier integrity. This compound is valuable for researching inflammatory pathways and therapeutic strategies in inflammatory bowel disease. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-2 is a PROTAC-based compound designed to target and degrade IRAK4, displaying potent degradation efficacy with a DC50 value of 151 nM in peripheral blood mononuclear cells (PBMCs). It effectively reduces IRAK4 protein levels, achieving a DC50 of 36 nM in these cells. Additionally, PROTAC IRAK4 Degrader-2 inhibits the production of multiple cytokines, making it a valuable tool for research in inflammation and immune response modulation. -
PROTAC IRAK4 Degrader
KTX-612 is an orally bioavailable IRAK4 PROTAC degrader with a DC50 value of 7 nM. This compound is designed to selectively target and promote the degradation of IRAK4, a key protein involved in inflammatory and oncogenic signaling pathways. KTX-612 has potential applications in oncology research, facilitating studies focused on the modulation of IRAK4 and its implications in cancer progression and treatment. -
IRAK4 ligand
IRAK4 ligand-13 is a selective ligand targeting IRAK4, a key component in the interleukin-1 receptor and Toll-like receptor signaling pathways. This compound is designed for the development of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It is suitable for research applications aimed at modulating immune responses and studying signaling pathways associated with inflammation and cancer. -
IRAK4 Inhibitor
BIO-8169 is a selective inhibitor of interleukin receptor-associated kinase 4 (IRAK4) with an IC50 of 0.23 nM. This compound demonstrates significant anti-inflammatory activity by reducing the production of pro-inflammatory cytokines. Additionally, BIO-8169 shows promising pharmacokinetic properties, including effective blood-brain barrier penetration, indicated by a rat Kpu,u of 0.7, making it suitable for investigating autoimmune conditions such as experimental autoimmune encephalomyelitis (EAE). -
IRAK3 Degrader PROTAC
PROTAC IRAK3 degrader-1 is a potent and selective degrader targeting IRAK3, with an IC50 of 5 nM. This compound effectively facilitates the ubiquitination and subsequent degradation of IRAK3, thereby modulating inflammatory responses. Its primary research applications include studies on innate immunity and the development of targeted therapies for inflammatory diseases. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 degrader-4 is a Cereblon-based bifunctional molecule designed to degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound facilitates targeted protein degradation, leading to effective modulation of IRAK4 levels in cells. Research applications include investigating inflammatory signaling pathways and therapeutic approaches for autoimmune diseases. -
PROTAC IRAK4 Degrader
KTX-497 is a potent IRAK4 degrader utilizing the PROTAC technology, exhibiting a DC50 value of 3 nM. This compound effectively targets and degrades IRAK4, making it a valuable tool for oncology research. Its mechanism allows for the selective modulation of signaling pathways implicated in cancer progression, facilitating the exploration of novel therapeutic strategies. -
PROTAC IRAK4 Degrader
KTX-955 is a potent IRAK4 degrader that facilitates the targeted degradation of IRAK4 protein. With DC50 values of 5 nM for IRAK4 and 130 nM for Ikaros, this compound demonstrates significant efficacy in modulating signaling pathways involved in tumorigenesis. KTX-955 comprises a CRBN ligand derived from Pomalidomide and a specific ligand targeting IRAK4, making it a valuable tool for research into cancer biology and therapeutic interventions. -
IRAK4 Inhibitor
IRAK4-IN-28 is a potent inhibitor of IRAK4, exhibiting an IC50 of 8.9 nM and a binding affinity characterized by a Kd of 0.58 nM. This compound is suitable for studies targeting inflammation and autoimmune diseases, providing valuable insights into the mechanisms of immune response modulation. Its selectivity and potency make it a useful tool for elucidating the role of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-15 is a selective inhibitor of IRAK4, demonstrating a remarkable IC50 of 0.002 µM. This compound exhibits favorable pharmacokinetic predictions in humans with low intrinsic clearance. In vitro studies reveal its potent synergistic activity against MyD88/CD79 double mutant ABC-DLBCL, particularly when used in combination with Acalabrutinib, positioning IRAK4-IN-15 as a valuable tool in cancer research. -
IRAK4 Inhibitor
IRAK4-IN-30 is a potent inhibitor of IRAK4, with an IC50 of 0.6 nM. This compound effectively modulates the signaling pathways associated with the innate immune response. It is valuable for research applications focused on inflammation, autoimmunity, and cancer, providing insights into the mechanistic roles of IRAK4 in various biological processes. -
IRAK4 Inhibitor
IRAK4-IN-17 is a potent inhibitor of IRAK4, exhibiting an IC50 of 1.3 nM. This compound is instrumental for research involving diffuse large B-cell lymphoma (DLBCL), providing insight into the role of IRAK4 in oncogenic signaling pathways. Its high specificity and efficacy make it a valuable tool for investigating therapeutic strategies targeting IRAK4-related mechanisms in cancer biology. -
IRAK4 Inhibitor
ND-2158 is a competitive inhibitor of IRAK4, exhibiting a Ki value of 1.3 nM. This compound effectively suppresses LPS-induced TNF production in human white blood cells and demonstrates therapeutic potential by alleviating collagen-induced arthritis and preventing gout formation in mouse models. Additionally, ND-2158 shows antitumor activity in vivo, making it a valuable tool for research in inflammation and cancer biology. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-10 is a potent IRAK4 degrader that utilizes a Cereblon ligand to initiate targeted protein degradation. It demonstrates remarkable biological activity, achieving a maximum degradation of 95.94% with a DC50 value of 7.68 nM in HEK293 cells. This compound is essential for research applications focused on inflammatory signaling pathways and therapeutic strategies targeting IRAK4. -
PROTAC IRAK4 Degrader
PROTAC IRAK4 Degrader-6 is a Cereblon-based PROTAC designed to selectively degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound targets IRAK4 for ubiquitination and subsequent proteasomal degradation, effectively modulating inflammatory signaling pathways. It is utilized in research applications focused on understanding the role of IRAK4 in immune responses and developing novel therapeutic strategies for inflammatory diseases. -
IRAK4 Inhibitor
IRAK4-IN-11 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), demonstrating a potent inhibition profile with an IC50 of 0.008 µM. This compound effectively suppresses phosphorylated IRAK4 with an IC50 of 0.19 µM, making it a valuable tool for studying the IL-1 signaling pathway. IRAK4-IN-11 is suitable for research applications focused on inflammation, immune response, and related therapeutic areas. -
IRAK4 Inhibitor
IRAK4-IN-19 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with an IC50 value of 4.3 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced IL-23 production in THP-1 and dendritic cells, demonstrating its ability to influence inflammatory pathways. IRAK4-IN-19 is valuable for research focused on arthritis and other inflammatory diseases, as it has shown efficacy in preventing the development of arthritis in animal models. -
IRAK4 Type II Inhibitor
HG-12-6 is a type II inhibitor of IRAK4, exhibiting preferential binding to unphosphorylated inactive IRAK4 with an IC50 of 165 nM. This compound effectively modulates IRAK4 activity, making it a valuable tool for studying its role in autoimmunity and inflammation. Researchers can utilize HG-12-6 to investigate pathways associated with immune responses and inflammatory disorders. -
IRAK Inhibitor
IRAK4-IN-25 is a potent inhibitor of IRAK4, with an IC50 of 7.3 nM, demonstrating significant oral bioavailability and low clearance (Cl=12 mL/min/kg). This compound effectively inhibits the production of pro-inflammatory cytokines, making it a valuable tool for studying inflammatory and autoimmune disorders. Its in vitro safety and ADME profiles further support its potential applications in research aimed at understanding immune response modulation. -
Ligand for IRAK4
IRAK4 ligand-14 is a selective ligand for the interleukin-1 receptor-associated kinase 4 (IRAK4). This compound can facilitate the synthesis of proteolysis-targeting chimeras (PROTACs), including APH02174. Its application in research primarily focuses on elucidating the role of IRAK4 in immune signaling pathways and developing innovative therapeutic strategies targeting IRAK4-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-24 is a potent inhibitor of IRAK4, a key kinase involved in the signaling pathways of inflammatory responses. This compound demonstrates significant biological activity, particularly in models of inflammatory and autoimmune disorders. IRAK4-IN-24 facilitates research into the modulation of immune responses and provides insights into potential therapeutic strategies targeting IRAK4 in various disease contexts. -
IRAK4 Inhibitor
IRAK4-IN-26 is a potent inhibitor of IRAK4 with an IC50 of 6.2 nM. This compound exhibits an oral bioavailability of 21%, making it suitable for in vivo studies. IRAK4-IN-26 is valuable for research into inflammatory and autoimmune disorders, facilitating the exploration of therapeutic strategies targeting IRAK4 signaling pathways. -
IRAK4 Inhibitor
BMS-978299 is a selective inhibitor of IRAK4, a critical kinase in the Toll-like receptor (TLR) signaling pathway. This compound demonstrates potent activity in modulating immune response and inflammation, making it a valuable tool for investigating immune disorders and related therapeutic interventions. Researchers can utilize BMS-978299 to further understand the role of IRAK4 in various pathophysiological conditions and to explore potential treatment strategies for immune-related diseases. -
IRAK4 Inhibitor
IRAK4-IN-34 is a potent and selective inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 of 0.73 nM. This compound demonstrates significant selectivity against hERG and other kinase targets. With favorable pharmacokinetic properties for in vivo applications, IRAK4-IN-34 is valuable for research into inflammatory diseases and related pathways. -
IRAK4 Inhibitor
ND-2110 is a selective inhibitor of IRAK4, exhibiting a binding affinity with a Ki of 7.5 nM. It effectively targets the ATP binding site of IRAK4 and demonstrates significant biological activity in activated B cell-like (ABC) subtype diffuse large B cell lymphoma (DLBCL) cell lines harboring MYD88 L265P mutations. ND-2110 has been shown to inhibit LPS-induced TNF production and demonstrates therapeutic potential in mouse models of collagen-induced arthritis and gout. -
Src
Canine Secretin is an endocrine hormone that primarily targets the Src kinase pathway. It stimulates the secretion of bicarbonate-rich pancreatic fluids and regulates gastric chief cell function, as well as paracellular permeability in canine gastric monolayers. This reagent is valuable for research applications involving gastrointestinal physiology and pancreatic function in canines. -
Src tyrosine kinase inhibitor
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck. - MLR 1023 is a selective allosteric activator of Lyn kinase (EC50 = 63 nM)
-
ABL/c-KIT dual kinase inhibitor
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor. -
CSF-1R Inhibitor
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1. -
multi-targeted tyrosine kinase inhibitor
Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. -
c-Met inhibitor
c-met-IN-1 (compound 16) is a potent and selective c-Met inhibitor, with IC50 of 1.1 nM, with antitumor activity. -
Eph receptor inhibitor
ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor. -
EGFR inhibitor
CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. -
PKC inhibitor
PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. -
CSF1R inhibitor
JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation. JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events. -
VEGFR inhibitor
NVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammation. -
Src Inhibitor
PP1 is a potent inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 5 and 6 nM respectively). Displays > 8000-fold selectivity over ZAP-70 and JAK2. Also moderately inhibits p38, CSK, PDGF receptors, RET-derived oncoproteins, c-Kit and Bcr-Abl
